Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arca Biopharma Inc (ABIO)

Arca Biopharma Inc (ABIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,480
  • Shares Outstanding, K 1,456
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,930 K
  • 60-Month Beta 1.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.97

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.07 +18.62%
on 06/19/19
7.77 -7.28%
on 06/26/19
+0.80 (+12.50%)
since 06/17/19
3-Month
5.01 +43.71%
on 04/30/19
20.45 -64.79%
on 05/02/19
+1.39 (+23.92%)
since 04/17/19
52-Week
4.68 +53.85%
on 12/28/18
23.04 -68.75%
on 07/31/18
-3.24 (-31.03%)
since 07/17/18

Most Recent Stories

More News
ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced it recently...

ABIO : 7.20 (unch)
ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial...

ABIO : 7.20 (unch)
GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the...

ABIO : 7.20 (unch)
ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the initial...

ABIO : 7.20 (unch)
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the...

ABIO : 7.20 (unch)
Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the...

ABIO : 7.20 (unch)
ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial...

ABIO : 7.20 (unch)
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug

-- 58% treatment benefit seen versus active comparator in Phase 2B for planned Phase 3 target population

ABIO : 7.20 (unch)
Demand for Cancer Treatment Remains High Despite Improving Survivability Rates

Deaths related to cancer dropped by 27% in the past quarter-century, meaning that 2.6 million fewer people died due to cancer during that time period, according to a report by the American Cancer Society....

ABIO : 7.20 (unch)
SESN : 1.31 (+1.55%)
NAVB : 0.64 (-4.48%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
CGIX : 0.19 (-8.86%)
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors

Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors.

LLY : 107.09 (-1.59%)
ABIO : 7.20 (unch)
ZSAN : 3.23 (-0.62%)
PRAH : 97.96 (-0.49%)
OCRX : 1.79 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ABIO with:

Business Summary

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular...

See More

Key Turning Points

2nd Resistance Point 7.60
1st Resistance Point 7.40
Last Price 7.20
1st Support Level 6.94
2nd Support Level 6.68

See More

52-Week High 23.04
Fibonacci 61.8% 16.03
Fibonacci 50% 13.86
Fibonacci 38.2% 11.69
Last Price 7.20
52-Week Low 4.68

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar